Genmab — Marts 2019
-
JNJ has announced that (NICE) has recommended Darzalex
(daratumumab) plus Velcade (bortezomib) and dexamethasone (DVd) for use within the Cancer Drugs Fund (CDF), as an option for treating relapsed multiple myeloma in people who have had one previous treatment. https://pharmafield.co.uk/pharma_news/nice-nod-for-game-changing-treatment-via-cdf-for-uk-myeloma-patients/ -
-
Endelig med nice
-
I 4. linie regnede de med ca 700 pts https://pharmaphorum.com/news/nice-backs-interim-funding-janssen-cancer-drug/
-
we are not there yet @Tandfeen-2 , still not 1st line and still via CDF, so far from ideal. But it is another step that will increase sales.
-
"NICE however said that the overall-survival data was ‘immature’ because more than half of the patients treated with the daratumumab combination were alive after nearly four years of follow up." this sounds like, if patients would have died quicker, it would have been easier to approve… crazy...
-
Interesting discussion between Janssen and Nice last year
. Dara could reset MM treatment https://www.nice.org.uk/guidance/ta510/documents/committee-papers-2 -
Ja,, kunne der komme et bud , så de hurtigt ville i 0 ,, det ville glæde mig at de brændte nallerne lidt...
-
Desværre også på en grøn dag
-
Genmab og Novo følges ad med minus 0,22 og 0,26% i dag. Værre er det ikke.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind